Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the approval of its investigational new drug, SKB535, by the National Medical Products Administration for clinical trials. This innovative ADC drug, developed using the company’s OptiDC platform, aims to treat advanced solid tumors and has already shown promising results in preclinical studies. The company has partnered with Merck & Co., Inc. to further develop SKB535, offering potential milestone payments and royalties upon successful commercialization.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.